"Not all hemoptysis is tuberculosis--think of other etiologies." A lesson from a chest clinic in a rural tertiary care center in central India.
Hemoptysis is the expectoration of blood that initiated in the lungs or bronchial tubes. A patient's history can aid in diagnosing the volume of blood and distinguish between hemoptysis, pseudohemoptysis, and hematemesis. An attentive physical evaluation can result in the detection in most cases.  The spitting of blood derived from the lungs or bronchial tree owing to pulmonary or bronchial hemorrhage is defined as hemotypsis.  The term "hemoptysis" originated from the Greek "haima," which means "blood," and "ptysis," which means "a spitting." Pseudohemoptysis is defined as blood not from lower respiratory tract but comes from above the vocal cords: mouth, pharynx, nose, aspiration of hematemsis, and colonization by gram-negative bacteria (Serratia marcescens)--prodigiosin pigment production. Hemoptysis had been graded depending on severity as massive: definition of massive hemoptysis varies from 100 mL/day to more than 1,000 mL/day with hemodynamic compromise, usually > 400 mL/day (5%-15% cases). Hence, mild: <100 mL/day; moderate: 100-400 mL/day; and massive: >400 mL/day. Hemoptysis is a frightening symptom for patients and often is a manifestation of a significant underlying disease such as tuberculosis, bronchiectasis, and lung cancer. Hence, blood expectoration even in small volume is a worrying sign, and massive (>400 mL/day) hemoptysis can be a life-threatening event. Therefore, hemoptysis of any grade requires detailed examination. Hemoptysis is a broad-spectrum symptom. However, in India, hemoptysis is nearly identical with pulmonary tuberculosis, and patients showing this symptom are frequently suggested antitubercular therapy without appropriate workup. The purpose of this study was to identify the various etiologies of hemoptysis and correct some common misconceptions regarding management of hemoptysis in tuberculosis.
Materials and Methods
We conducted this prospective study with 462 patients at the chest clinic of Department of Pulmonary Medicine at UP Rural Institute of Medical Sciences and Research, Saifai, Uttar Pradesh, India, between the period of June 2011 and December 2014. Before doing the study, we obtained informed consent from the patients and the institutional ethical committee. Demographic data, including sex and age, were collected. Patients were also grouped into categories on the basis of their primary diagnosis (i.e., pulmonary tuberculosis, neoplasm, chronic bronchitis, bronchiectasis, and "other"). Diagnosis was made after thorough clinical evaluation and appropriate investigations such as chest radiography, computed tomography (CT) of thorax, and bronchoscopy.
Diagnosis of pulmonary tuberculosis was based on chest radiography and sputum examination for acid-fast bacilli (AFB) in our Revised National Tuberculosis Control Programme (RNTCP) laboratory under fluorescent microscopy. A chest radiograph exhibiting nodular, alveolar, or interstitial infiltrates chiefly impacting the upper area of the lung in symptomatic patients (i.e., those with cough, weight loss, and fever with night sweat) was regarded as indicative of pulmonary tuberculosis. When the chest radiograph showed inactive processes such as calcified granuloma, fibrosis, and sputum AFB negative and there were no symptoms other than hemoptysis, the patient was diagnosed as having inactive pulmonary tuberculosis. For bronchogenic carcinoma, diagnosis was based on histopathology. Bronchitis was diagnosed when a patient showed symptoms consistent with upper airway infection and a normal chest radiograph. Diagnosis of bronchiectasis was confirmed by high-resolution CT of thorax.
All patients were given conservative treatment for the control of hemoptysis, irrespective of the amount of blood expectorated, along with necessary measures for management of the primary disease. The conservative treatment comprised absolute bed rest in depended side down, tranexamic acid injection, cough suppressant such as codeine, mild sedation with alprazolam, antibiotics, and other supportive measures.
During the study period, we conducted our research on 462 patients attending our Department of Pulmonary Medicine clinic. Then, based on primary diagnosis for hemoptysis, they were categorized. Pulmonary tuberculosis was the leading cause but highest being those who are inactive, sputum-negative sequelae of old-treated pulmonary tuberculosis (110, 24%). Similarly, bronchiectasis was found in 92 (20%) subjects; sputum-positive pulmonary tuberculosis, 73 (16%); chronic obstructive pulmonary disease (COPD)/ emphysema, 46 (10%); chronic bronchitis, 27 (6%); pneumonia, 27 (6%); aspergilloma, 23 (5%); lung carcinoma, 11 (2.5%); URTI/LRTI, 14 (3%); mitral stenosis, 9 (2%); middle lobe syndrome, 9 (2%); lung abscess, 11 (2.38%); diffuse alveolar hemorrhage, 6 (1.3%), and cannabis smoker with bullae, 4 (0.86%). Of them, 140 (30.3%) patients--40 (28.6%) patients with inactive pulmonary tuberculosis, 50 (35.7%) patients with hemoptysis of non-tubercular etiology, and 50 (35.7%) with bronchiectasis--were misdiagnosed as active pulmonary tuberculosis and prescribed antitubercular drugs before coming to our department [Table 1]. All the patients were treated conservatively with bed rest, cough suppressants, sedative, and other supportive care.
This study conducted at our institution is an eye opener regarding the etiological possibilities of patients presenting with hemoptysis to the clinic of a physician. During our study, we experienced default diagnosis of cases as pulmonary tuberculosis and unnecessary use of antitubercular drugs being practiced in this region. Pulmonary tuberculosis was the most common cause of hemoptysis four decades ago as shown by Rao in his study in 1960,  and it is still the leading cause of it as is evident from this study, in which tuberculosis was found in 40% of patients with hemoptysis. Various studies from other developing countries have also shown pulmonary tuberculosis to be the major cause of hemoptysis. [4-7] We also found bronchiectasis being the second most leading cause (92,20%) for hemoptysis in this region, very often being misdiagnosed and treated with antitubercular therapy by the physicians. Probably, the reasons were lack of awareness, training, and nonguideline-based prescription of antitubercular drugs. Studies from developed countries have shown malignancy and nontuberculous causes to be the leading reasons for hemoptysis.  In a retrospective study from United States, acute bronchitis was the most common cause of hemoptysis, followed by bronchogenic carcinoma.  The incidence of malignancy in various other studies from the developed world has ranged from 5% to 44% [10-16]; in comparison, in this study, carcinoma lung was 2.5% only. Cases were referred to us with hemoptysis as sign of multidrug-resistant tuberculosis or active tuberculosis; however, we found 24% cases were sputum-negative healed posttubercular fibrosis, 16% were sputum positive for AFB, and 20% cases were bronchiectasis.
Hence, hemoptysis occurring in a patient during the course of treatment (of tuberculosis) does not mean that the patient is not responding or that the infection is drug resistant. There may be lack of awareness among general physicians about the various causes of hemoptysis or causes in pulmonary tuberculosis patients. One limitation of our study was that owing to nonavailability of advanced techniques in our hospital; we could not provide optimum care for patients with massive hemoptysis.
Pulmonary tuberculosis is still the major cause of hemoptysis in developing countries such as India. Hemoptysis does not always reflect underlying pulmonary tuberculosis. Hence, antitubercular treatment (ATT) should not be started without proper diagnostic workup. Hemoptysis can occur during the course of ATT; hemoptysis in a case of pulmonary tuberculosis, which otherwise shows clinical, radiological, and bacteriological improvement, does not always indicate drug-resistant tuberculosis. Hemoptysis does not require the start of ATT in a successfully healed patient who does not show any clinicoradiobacteriological indication of active pulmonary tuberculosis. Tuberculosis should not be overdiagnosed, and unnecessary use of antitubercular drugs should be stopped. Other diagnosis for hemoptysis should be evaluated. Specialist opinion is important for starting antitubercular drugs.
It is clear from the study that pulmonary tuberculosis and its sequelae still holds the leading cause of hemoptysis in our region of study with bronchiectasis being the second most common. Many patients of bronchiectasis are being misdiagnosed as tuberculosis and put on ATT. Hence, raising awareness among general physicians is the point of discussion of this study.
[1.] Bidwell JL, Pachner RW. Hemoptysis: diagnosis and management. Am Fam Physician 2005;72:1253-60.
[2.] Prasad R, Garg R, Singhal S, Srivastava P. Lessons from patients with hemoptysis attending a chest clinic in India. Ann Thorac Med 2009;4(1):10-2.
[3.] Rao PU. Haemoptysis as a symptom in a chest clinic. Indian J Chest Dis 1960;2:219.
[4.] Ashraf O. Hemoptysis: a developing world perspective. BMC Pulm Med 2006;6:1.
[5.] Abal AT, Nair PC, Cherjan J. Haemoptysis: Aetiology, evaluation and outcome--a prospective study in a third-world country. Respir Med 2001;95:548-52.
[6.] Stebbings AE, Lim TK. Cause, treatment and outcome of patients with life-threatening haemoptysis. Singapore Med J 1999; 40:67-9.
[7.] Domoua K, N'Dhatz M, Coulibaly G, Aka-Danguy E, Traore F, et al. [Hemoptysis: main etiologies observed in a pneumology department in Africa]. Rev Pneumol Clin 1994;50:59-62.
[8.] Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997;112:440-4.
[9.] Reisz G, Stevens D, Boutwell C, Nair V. The causes of hemoptysis revisited. A review of the etiologies of hemoptysis between 1986 and 1995. Mo Med 1997;94:633-5.
[10.] Johnston RN, Lockhart W, Ritchie RT, Smith DH. Haemoptysis. Br Med J 1960;1:592-5.
[11.] Santiago S, Tobias J, Williams AJ. A reappraisal of the causes of hemoptysis. Arch Intern Med 1991;151:2449-51.
[12.] Pursel SE, Lindskog GE. Hemoptysis. A clinical evaluation of 105 patients examined consecutively on a thoracic surgical service. Am Rev Respir Dis 1961;84:329-36.
[13.] van Kralingen KW, van Kralingen-Heijboer AC, Zimmerman M, Postmus PE. Management of hemoptysis in a Third World city hospital: a retrospective study. Tuber Lung Dis 1995;76:344-8.
[14.] Souders CR, Smith AT. The clinical significance of hemoptysis. N Engl J Med 1952;247:790-3.
[15.] Moersch HJ. Clinical significance of hemoptysis. JAMA 1952; 148:1461-5.
[16.] Baric D. The origin of hemoptysis in patients admitted to the pneuno-phtisiology department of the Zadar Hospital between 1970 and 1980. Bull IUAT 1984;59:205-6.
Source of Support: Department of Biotechnology (DBT), Government of India, Conflict of Interest: None declared.
Adesh Kumar, Ashish Kumar Gupta, Aditya Kumar Gautam, Somnath Bhattacharya, Prashant Yadav, Bal Krishna Kushwaha
Department of Pulmonary Medicine, UP Rural Institute of Medical Sciences and Research Saifai, Etawah, Uttar Pradesh, India.
Correspondence to: Prashant Yadav, E-mail: firstname.lastname@example.org
Received October 8, 2015. Accepted December 14, 2015
Table 1: Etiology of hemoptysis Etiology-primary diagnosis Total number (%) Sputum AFB (-ve) pulmonary tuberculosis 110 (24) sequelae Bronchiectasis 92 (20) Sputum AFB +ve pulmonary tuberculosis 73 (16) COPD/emphysema 46 (10) Chronic bronchitis 27 (6) Pneumonia 27 (6) Aspergilloma 23 (5) URTI/LRTI 14 (3) Carcinoma lung 11 (2.5) Mitral stenosis 9 (2) Middle lobe syndrome 9 (2) Lung abscess 11 (2.38) Diffuse alveolar hemorrhage 6 (1.3) Cannabis smoker/bullae 4 (0.86)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Research|
|Author:||Kumar, Adesh; Gupta, Ashish Kumar; Gautam, Aditya Kumar; Bhattacharya, Somnath; Yadav, Prashant; Kus|
|Publication:||International Journal of Medical Science and Public Health|
|Date:||Aug 1, 2016|
|Previous Article:||Role of peripherin in defining specific populations of cell bodies in the dorsal root ganglia.|
|Next Article:||Estimation of serum amyloid A protein in neonatal sepsis: a prospective study.|